Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 November 2021Website:
http://www.vaxxinity.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 07 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
VAXX Latest News
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Vaxxinity stock is experiencing a rise on Friday with significant pre-market trading activity, with over 21 million shares being traded at the moment.
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November.
The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress
What type of business is Vaxxinity?
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
What sector is Vaxxinity in?
Vaxxinity is in the Healthcare sector
What industry is Vaxxinity in?
Vaxxinity is in the Biotechnology industry
What country is Vaxxinity from?
Vaxxinity is headquartered in United States
When did Vaxxinity go public?
Vaxxinity initial public offering (IPO) was on 11 November 2021
What is Vaxxinity website?
https://www.vaxxinity.com
Is Vaxxinity in the S&P 500?
No, Vaxxinity is not included in the S&P 500 index
Is Vaxxinity in the NASDAQ 100?
No, Vaxxinity is not included in the NASDAQ 100 index
Is Vaxxinity in the Dow Jones?
No, Vaxxinity is not included in the Dow Jones index
When was Vaxxinity the previous earnings report?
No data
When does Vaxxinity earnings report?
Next earnings report date is not announced yet